Morgan Stanley Acts as Lead Bookrunning Manager for Yesway Secondary Offering
Morgan Stanley is serving as the lead bookrunning manager for a secondary offering of 5,000,000 shares of Yesway, Inc. Class A common stock.
Stocks · News reference
Blue Owl, Ares Management, Blackstone, and Apollo Global stocks have retreated into a correction as private credit risks remain
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley is serving as the lead bookrunning manager for a secondary offering of 5,000,000 shares of Yesway, Inc. Class A common stock.
The article compares CME Group and Upstart as investment options for 2027. CME Group is a mature, profitable derivatives marketplace with $4 billion in net income, low leverage, and strong free cash flow of $4.2 billion, trading at a lower forward P/E of 25.8. Upstart is a high-growth AI-powered lending platform with 64% revenue growth but carries higher leverage (debt-to-equity of 2.3), negative free cash flow of $166.1 million, and a higher forward P/E of 48.6. The author recommends CME Group for investors seeking stability and dividends, while Upstart appeals to growth-focused investors.
Global investment firm KKR and Carlyle have committed approximately $475 million in new capital to music rights investment and management business Litmus Music.
OMERS and Transmission Developers Infrastructure (TDI), a Blackstone portfolio company, have partnered to bid on the Independent Electricity System Operator's Toronto Third Line procurement.
Blue Owl Capital has entered into a $3.4 billion joint venture with Crusoe and Primary Digital Infrastructure for AI data center development, alongside a second phase of a $15 billion joint venture in Abilene, Texas.
Medline Inc. announced the pricing of a secondary offering of 60 million Class A common shares at $35.50 per share by selling stockholders affiliated with Blackstone, Carlyle Group, Hellman & Friedman, GIC Private Limited, and Abu Dhabi Investment Authority. The offering is expected to close on November 23, 2026. Medline will not receive proceeds from the sale but has agreed to repurchase $200 million of its own stock and Common Units from the selling stockholders at the same price.